Cytokine Therapy of Metastatic Renal Cell Carcinoma: The Cleveland Clinic Experience

  • R. M. Bukowski
  • T. Olencki
  • D. Peereboom
  • G. T. Budd
  • S. Murthy
  • R. Tubbs
  • P. Rayman
  • D. McLain
  • E. Klein
  • L. Tuason
  • J. Finke
Conference paper


The incidence of renal cell carcinoma in the United States appears to be increasing, and in 1994 will cause an estimated 11,300 deaths (1). Patients with resectable disease have a five year survival of approximately 50% (2), and those individuals presenting with regionally advanced or metastatic disease have five year survival rates of less than 5% (3). The rare spontaneous regression of established metastatic disease (4) has produced speculation that host factors may be relevant in controlling tumor growth. Recently, studies demonstrating the presence of specific cytolytic T-lymphocytes in tumor infiltrating lymphocytes isolated from renal cancers (5, 6) have documented the existence of a host immune response to this tumor. In the 1980’s, the clinical use of first recombinant interferon alpha (7) and subsequently interleukin-2 (rIL-2) (8, 9) was investigated in patients with metastatic renal cell carcinoma. The clear demonstration of objective tumor regressions secondary to administration of these cytokines has been followed by a period of increasing interest in the use of various biologic response modifiers in this neoplasm. At The Cleveland Clinic Foundation, we have systematically evaluated the biologic and clinical effects of various cytokines in patients with malignancy during the past 15 years. The purpose of this report is to summarize the experience in patients with metastatic renal cell cancer.


Renal Cell Carcinoma Peripheral Blood Lymphocyte Cleveland Clinic Metastatic Renal Cell Carcinoma Tumor Infiltrate Lymphocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boring CC, Squires TS, Tong T, Montgomery S: Cancer Statistics 1994. CA Cancer J Clin 44:7–26, 1990.CrossRefGoogle Scholar
  2. 2.
    Myers MH, Gloeckler LA: Cancer patient survival rates: SEER program results for 10 years of follow-up. CA Cancer J Clin 39:21–32, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Patel NP, Livengood RW: Renal cell cancer: natural history and results of treatment. J Urol 119:722–726, 1977.Google Scholar
  4. 4.
    Fairlamb DJ: Spontaneous regression of metastases of renal cancer. A report of two cases including the first recorded regression following irradiation of a dominant metastasis and review of the world literature. Cancer 47:2101–2106, 1981.CrossRefGoogle Scholar
  5. 5.
    Finke JH, Rayman P, Hart L et al: Characterization of tumor -infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-secretion, and proliferation. J Immunother 15:91–104, 1994.CrossRefGoogle Scholar
  6. 6.
    Koo AS, Tso CL, Shimabukuro T, et al: Autologous tumor-specific cytotoxicity of tumor-infiltrating lymphocytes derived from human renal cell carcinoma. J Immunother 10:347–54, 1991.PubMedCrossRefGoogle Scholar
  7. 7.
    Muss HB: Renal Cell Carcinoma. In: Biologic Therapy of Cancer, eds. DeVita VT, Hellman S, Rosenberg SA, JB Lippincott Co., Phil., PA, pp 298–311, 1991.Google Scholar
  8. 8.
    Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907–913, 1994.PubMedCrossRefGoogle Scholar
  9. 9.
    Bukowski RM, Goodman P, Crawford ED, et al: Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J Natl Cancer Inst 82:143–146, 1990.PubMedCrossRefGoogle Scholar
  10. 10.
    Erard F, Corthesy P, Nabholz M, et al: Interleukin-2 is both necessary and sufficient for growth and differentiation of lectin-stimulated cytolytic T-lymphocyte precursors. J Immunol 134:1644–1651, 1985.PubMedGoogle Scholar
  11. 11.
    Smith KA: Interleukin-2: inception, impact, and implications. Science 240:11691176,1988.Google Scholar
  12. 12.
    Lafreniere R, Rosenberg SA: Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin2 (rIL-2) can mediate the regression of both immunogenic and non-immunogenic sarcomas and an adenocarcinoma. J Immunol 135:4273–4280, 1985.PubMedGoogle Scholar
  13. 13.
    Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid interferon-alpha in treatment of established murine hepatic metastases. Cancer Res 48:5810–5817, 1988.PubMedGoogle Scholar
  14. 14.
    West WH, Tauer KW, Yanelli JR, et al: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316:898–905, 1987.PubMedCrossRefGoogle Scholar
  15. 15.
    DeLena M, Casamassima A, Guida M, et al: Subcutaneous rIL-2 in advanced melanoma and kidney carcinoma. Int J Oncol 1:181–187, 1992.Google Scholar
  16. 16.
    Knauf MJ, Bell DP, Hertzer P, et al: Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water soluble polymers. J Biol Chem 263:15064–15070, 1988.PubMedGoogle Scholar
  17. 17.
    Meyers FJ, Paradise C, Scudder SA, et al: A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2. Clin Pharmacol Ther 49:307–313, 1991.PubMedCrossRefGoogle Scholar
  18. 18.
    Bukowski RM, Young J, Goodman G, et al: Polyethylene glycol conjugated interleukin-2; clinical and immunologic effects in patients with advanced renal cell carcinoma. Inv New Drugs 11:211–217, 1993.CrossRefGoogle Scholar
  19. 19.
    Minasian LM, Motzer RJ, Gluck L, et al: Interferon alpha-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. J Clin Oncol 11:1368–1375, 1993.PubMedGoogle Scholar
  20. 20.
    Rosenberg SA, Lotze MT, Yang JC, et al: Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85:622–632, 1993.PubMedCrossRefGoogle Scholar
  21. 21.
    Bukowski RM, Sergi J, Sharfman WJ, et al: Phase I trial of natural human interferon beta (nHuIFN(3) in metastatic malignancy. Cancer Res 51:836–840, 1991.PubMedGoogle Scholar
  22. 22.
    Barna BP, Thomassen MJ, Sergi J, et al: Immunologic changes in renal cell carcinoma patients receiving gamma interferon. Oncology 48:464–468, 1991.PubMedCrossRefGoogle Scholar
  23. 23.
    Fidler IJ, Sone S, Fogler WE, Barnes ZL: Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78:1680–1684, 1981.PubMedCrossRefGoogle Scholar
  24. 24.
    Metcalf D, Begley CG, Johnson GR, et al: Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 67:37–45, 1986.PubMedGoogle Scholar
  25. 25.
    Thomassen MJ, Barna BP, Rankin D, et al: Differential effect of recombinant granulocyte-macrophage colony-stimulating factor on human monocytes and alveolar macrophages. Cancer Res 49:4086–4089, 1989.PubMedGoogle Scholar
  26. 26.
    Bukowski RM, Murthy S, McLain D, et al: Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer; clinical and immunologic effects. J Immunother 13:267–274, 1993.CrossRefGoogle Scholar
  27. 27.
    Bukowski RM, McLain D, Sergi J, et al: Phase II trial GM-CSF in metastatic renal cell cancer (RCC). Proc Am Assoc Cancer Res 34:212, 1993(abstract).Google Scholar
  28. 28.
    Dranoff G, Jaffee EM, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secret murine GM-CSF stimulates potent, specific and long lasting antitumor immunity. Proc Natl ACAD SCI USA 90:3539–3543, 1993.PubMedCrossRefGoogle Scholar
  29. 29.
    Tosato G, Seamon KB, Goldman ND, et al: Monocyte derived human B-cell growth factor identified as interferon-2 (BSF-2, IL-6). Science 239:502–504, 1988.PubMedCrossRefGoogle Scholar
  30. 30.
    Van Damme J, Opdenakker G, Simpson RJ: Identification of the human 26kD protein, interferon beta-2 (IFN 2) as a B cell hybridoma/plasmacytoma growth factor induced by interleukin and tumor necrosis factor. J Exp Med 165:914–920, 1987.PubMedCrossRefGoogle Scholar
  31. 31.
    Uyttenhove C, Coulie PG, Van Snick J: T cell growth and differentiation induced by interleukin-HP1/IL-6, the murine hybridoma/plasmacytoma growth factor. J Exp Med 167:1417–1427, 1988.CrossRefGoogle Scholar
  32. 32.
    Ishibashi T, Kimura H, Shikama Y, et al: Interleukin-6 is a potent thrombopoietic factor in vivo in mice. Blood 74:1241–1244, 1989.PubMedGoogle Scholar
  33. 33.
    Gauldie J, Richards C, Harrish D, et al: Interferon 2/B cell stimulatory factor-2 shares identify with monocyte derived hepatocyte stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251–7255, 1987.PubMedCrossRefGoogle Scholar
  34. 34.
    Mule JJ, McIntosh JK, Jablons DM, et al: In vivo administration of recombinant interleukin-6 mediates tumor regression in mice. J Exp Med 171:629–637, 1990.PubMedCrossRefGoogle Scholar
  35. 35.
    Olencki T, Rayman P, Tauson L, et al: Antitumor effects of IL-6 alone and in combination with IL-2 and/or cyclophosphamide in the weakly immunogenic mutine RENCA tumor. Proc Am Assoc Cancer Res 35:525, 1994(abstract).Google Scholar
  36. 36.
    Mule JJ, Custer MC, Travis WD, et al: Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 148:2622–2626, 1992.PubMedGoogle Scholar
  37. 37.
    Koo AS, Armstrong C, Bochner B, et al: Interleukin-6 and renal cancer: production, regulation and growth effects. Cancer Immunol Immunother 35:97105, 1992.CrossRefGoogle Scholar
  38. 38.
    Kerger J, De Greve J, Piccart MJ, et al: A phase I clinical trial of recombinant human interleukin-6 (rhIL-6, ILS969) in advanced solid tumors. 8th NCI-EORTC Symposium of New Drugs in Cancer Therapy p109, 1994.Google Scholar
  39. 39.
    Ihle JN, Keller J, Oronzlan S, et al: Biologic properties of homogenous interleukin 3.1. Demonstration o f WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol 131:282–287, 1983.PubMedGoogle Scholar
  40. 40.
    Leary AG, Yang YC, Clark SC, et al: Recombinant gibbon interleukin 3 supports formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage colony-stimulating factor. Blood 70:1343–1348, 1987.PubMedGoogle Scholar
  41. 41.
    Sonoda Y, Yang YC, Wong GG, et al: Analysis in serum-free culture o f the targets of recombinant human hematopoietic growth factors: interleukin 3 and granulocyte-macrophage colony-stimulating factor are specific for early development stages. Proc Natl Acad Sci USA 85:4360–4364, 1988.PubMedCrossRefGoogle Scholar
  42. 42.
    Santoli D, Clark SC, Kreider BL, et al: Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol 141:519–526, 1988.PubMedGoogle Scholar
  43. 43.
    Thomassen MJ, Antal JM, Connors MJ, et al: Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytes. J Immunother 14:43–50, 1993.CrossRefGoogle Scholar
  44. 44.
    Bukowski RM, Olencki T, Murthy S, et al: Modulation of T-lymphocytes by interleukin-3 (rIL-3) in vivo: results of a phase I trial in patients with malignancy. Proc Am Assoc Cancer Res 35:525, 1994(abstract).Google Scholar
  45. 45.
    Bukowski RM, Budd GT, Gibbons JA, et al: Phase I trial of subcutaneous recombinant macrophage colony stimulating factor: clinical and immunomodulatory effects. J Clin Oncol 12:97–106, 1994.PubMedGoogle Scholar
  46. 46.
    Sanda MG, Yang JC, Topalian SL, et al: Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study. J Clin Oncol 10:1643–1649, 1992.PubMedGoogle Scholar
  47. 47.
    Rayman P, Finke JH, Olencki T, et al: Adoptive immunotherapy utilizing IL-2 and IL-4 for expansion of tumor infiltrating lymphocytes in renal cell carcinoma. In: Immunotherapy of Cancer with Sensitized Lymphocytes, eds: Change AE, Shu S. (1994, in press).Google Scholar
  48. 48.
    Spits H, Yssel H, Paliard X, et al: IL-4 inhibits IL-2 mediated induction of human lymphokine-activated killer cells, but not the generation of antigen-specific cytotoxic T lymphocytes in mixed leukocyte cultures. J Immunol 141:29–36, 1988.PubMedGoogle Scholar
  49. 49.
    Cameron RB, McIntosh JK, Rosenberg SA: Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid interferon-alpha in treatment of established murine hepatic metastases. Cancer Res 48:5810–5817, 1988.PubMedGoogle Scholar
  50. 50.
    Budd GT, Osgood B, Barna B, et al: Phase I clinical trial of interleukin-2 and - interferon: toxicity and immunologic effects. Cancer Res 49:6432–6436, 1989.PubMedGoogle Scholar
  51. 51.
    Budd GT, Murthy S, FinkeJ, et al: Phase I trial of high dose bolus IL-2 and IFN2a in patients with metastatic malignancy. J Clin Oncol 10:804–809, 1992.PubMedGoogle Scholar
  52. 52.
    Bukowski RM, Murthy S, Sergi J, et al: Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-2a: clinical effects, J Biol Resp Modifiers 9:538–545, 1990.Google Scholar
  53. 53.
    Olencki T, Finke J, Tubbs R, et al: Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy: results of a phaseI trial (submitted).Google Scholar
  54. 54.
    Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alpha-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 11:1809–1816, 1993.PubMedGoogle Scholar
  55. 55.
    Alexander JP, Kudoh S, Melsop KA, et al: T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin2 and express interleukin-2 receptors. Cancer Res, 53:1380–1387, 1993.PubMedGoogle Scholar
  56. 56.
    Miescher S, Stoeck M, Quiao L, et al: Proliferative and cytolytic potential of purified human tumor-infiltrating T-lymphocytes. Impaired response to mitogendriven stimulation despite T-cell receptor expression. Int J Cancer, 42:659–666, 1988.PubMedCrossRefGoogle Scholar
  57. 57.
    Finke JH, Zea AH, Stanley J, et al: Loss of T-cell receptor chain and p561`k in T-cells infiltrating human renal cell carcinoma. Cancer Res, 53:5613–5616, 1993.PubMedGoogle Scholar
  58. 58.
    Wang Q, Tubbs R, Klein E, et al: Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor infiltrating lymphocytes (submitted).Google Scholar
  59. 59.
    Malefyt R, de Waal R, Yssel H, de Vries JE: Direct effect of IL-10 on subsets of human CD4+ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 150:44754–4765, 1993.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1995

Authors and Affiliations

  • R. M. Bukowski
    • 1
    • 2
  • T. Olencki
    • 1
    • 2
  • D. Peereboom
    • 1
    • 2
  • G. T. Budd
    • 1
    • 2
  • S. Murthy
    • 1
    • 2
  • R. Tubbs
    • 3
  • P. Rayman
    • 4
  • D. McLain
    • 1
  • E. Klein
    • 5
  • L. Tuason
    • 6
  • J. Finke
    • 4
  1. 1.Cancer Center Experimental Therapeutics ProgramThe Cleveland Clinic FoundationClevelandUSA
  2. 2.Department of Hematology and Medical OncologyThe Cleveland Clinic FoundationClevelandUSA
  3. 3.Department of Clinical PathologyThe Cleveland Clinic FoundationClevelandUSA
  4. 4.Department of ImmunologyThe Cleveland Clinic FoundationClevelandUSA
  5. 5.Department of UrologyThe Cleveland Clinic FoundationClevelandUSA
  6. 6.Department of Biostatistics EpidemiologyThe Cleveland Clinic FoundationClevelandUSA

Personalised recommendations